Integrated BioPharma, Inc. (INBP)
OTCMKTS · Delayed Price · Currency is USD
0.1603
+0.00961 (6.38%)
At close: Aug 7, 2026
Integrated BioPharma Financials Overview
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Revenue Revenue Growth | 48.25 | 54.35 | 50.32 | 50.67 | 56.25 | 63.56 |
Revenue Growth | -8.83% | 8.02% | -0.70% | -9.91% | -11.51% | 20.45% |
Gross Profit Gross Profit Growth | 2.24 | 5.56 | 3.88 | 4.06 | 6.55 | 9.48 |
Operating Income Operating Income Growth | -1.25 | 2.02 | 0.25 | 0.12 | 2.75 | 5.78 |
Net Income Net Income Growth | -1.65 | 0.81 | 0.11 | -0.03 | 3.84 | 8.01 |
Earnings Per Share EPS Growth | -0.05 | 0.03 | 0.00 | -0.00 | 0.12 | 0.25 |
EPS Growth | - | 635.32% | - | - | -52.00% | 92.31% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Contract Manufacturing Contract Manufacturing Growth | 46.49 | 51.68 | 48.57 | 48.28 | 54.09 | 61.84 |
Other Nutraceutical Businesses Other Nutraceutical Businesses Growth | 1.76 | 2.67 | 1.75 | 2.4 | 2.16 | 1.72 |
Total Total Growth | 48.25 | 54.35 | 50.32 | 50.67 | 56.25 | 63.56 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Cash & Investments Cash & Investments Growth | 5.83 | 3.62 | 1.68 | 1.32 | 0.34 | 0.28 |
Total Debt Total Debt Growth | 3.35 | 1.02 | 1.8 | 2.67 | 2.06 | 6 |
Net Cash (Debt) Net Cash Growth | 2.48 | 2.6 | -0.12 | -1.36 | -1.71 | -5.72 |
Net Cash Growth | 35.89% | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | 0.08 | 0.08 | -0.00 | -0.05 | -0.05 | -0.18 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 3.03 | 2.07 | 0.94 | 1.23 | 4.09 | 3.05 |
Capital Expenditures CapEx Growth | -0.19 | -0.19 | -0.55 | -0.12 | -0.49 | -0.3 |
Free Cash Flow Free Cash Flow Growth | 2.84 | 1.87 | 0.39 | 1.12 | 3.61 | 2.76 |
Free Cash Flow Growth | 201.70% | 380.51% | -65.05% | -69.04% | 30.85% | 144.89% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Gross Margin | 4.64% | 10.23% | 7.72% | 8.01% | 11.65% | 14.92% |
Operating Margin | -2.58% | 3.72% | 0.50% | 0.24% | 4.88% | 9.10% |
Pretax Margin | -2.32% | 3.79% | 0.53% | 0.20% | 4.62% | 11.40% |
Profit Margin | -3.43% | 1.49% | 0.22% | -0.07% | 6.82% | 12.61% |
FCF Margin | 5.88% | 3.45% | 0.78% | 2.20% | 6.41% | 4.33% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 11, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
PE Ratio | - | 13.72 | 56.44 | - | 3.90 | 4.09 |
P/FCF Ratio | 1.75 | 5.92 | 16.21 | 8.89 | 4.15 | 11.90 |
PS Ratio | 0.10 | 0.20 | 0.13 | 0.20 | 0.27 | 0.52 |